This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Novo Nordisk continues to sling obesity drug partnerships. Its latest biotech of...
Cell and gene therapy advocacy organizations are jointly calling for a 10-year i...
On Friday afternoon, Ngai, Shelby and I dropped what we were doing when we saw O...
An order from a federal appeals court has kicked the battle wide open again over...
The Trump administration laid out for the first time how Part B drugs could be s...
A handful of generic and biosimilar manufacturers have said they feel prepared t...
Arcturus Therapeutics is doubling down on mRNA technology. The biotech said ...
Cytokinetics’s aficamten is better than the standard of care in a heart muscle d...
Plus, news about Neumora, Erasca, FibroGen, Tilt Biotherapeutics, Sangamo, Leap ...
Andrew Witty is out as CEO of UnitedHealth Group after a tumultuous couple of ye...
At last year's ESMO conference, there was hope that the TIGIT field still had a ...
Today on Post Hoc Live, Drew Armstrong is joined by Nick Shipley, the former top...
Today on Post Hoc Live, Drew Armstrong is joined by Nick Shipley, the former top...
A month ago, former AbbVie and Neumora executive Henry Gosebruch was named the C...
Bayer has been ramping up its layoff count in recent months as it edges closer t...
The last time Dutch biotech Azafaros disclosed a financing round — a €25 million...